Compare CHGG & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHGG | FBIO |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.4M | 88.7M |
| IPO Year | 2013 | N/A |
| Metric | CHGG | FBIO |
|---|---|---|
| Price | $0.88 | $3.32 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $1.42 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 1.8M | 313.3K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $447,733,000.00 | $62,303,000.00 |
| Revenue This Year | N/A | $29.71 |
| Revenue Next Year | N/A | $49.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.44 | $1.33 |
| 52 Week High | $2.40 | $4.20 |
| Indicator | CHGG | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 71.98 |
| Support Level | $0.83 | $2.49 |
| Resistance Level | $1.03 | $3.00 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 27.50 | 86.66 |
Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Subscription Services, which encompasses Chegg Study Pack, Chegg Study, Chegg Writing, Chegg Math, and Busuu offerings that can be accessed internationally through the company's websites and on mobile devices, and Skills and Other, which encompasses skills, advertising services, print textbooks, and eTextbooks offerings.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.